Business Context and Reporting Period
Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1998
Business Overview: Regeneron is a biotechnology company focused on discovering and developing protein-based and small-molecule therapeutics. The company has no commercial product sales and relies on revenue from research collaborations, contract manufacturing, and investment income. Key programs include AXOKINE (obesity/diabetes), BDNF and NT-3 (ALS/constipation), angiogenesis, and cytokine antagonists.
Key Financial Metrics (Year Ended Dec 31, 1998)
| Metric | 1998 | 1997 | 1996 |
|---|---|---|---|
| Total Revenue | $45.2 million | $33.1 million | $24.1 million |
| Net Loss | ($8.6 million) | ($11.6 million) | ($32.4 million) |
| Net Loss Per Share | ($0.28) | ($0.40) | ($1.33) |
| Research & Development Expenses | $37.0 million | $27.8 million | $28.3 million |
| Cash & Cash Equivalents | $19.8 million | $28.9 million | $34.5 million |
| Marketable Securities | $93.8 million | $99.1 million | $97.0 million |
| Total Liquidity (Cash + Securities) | $113.5 million | $128.0 million | $97.0 million |
| Accumulated Deficit | ($177.2 million) | ($168.6 million) | ($157.0 million) |
| Long-Term Debt | $3.1 million | $3.8 million | $5.1 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 36.5% to $45.2 million, driven by higher contract research revenue from the Procter & Gamble (P&G) agreement and increased contract manufacturing revenue from Merck.
- Improved Loss Profile: Net loss narrowed by 25.5% to $8.6 million, primarily due to reduced losses from the Amgen-Regeneron Partners partnership ($2.5 million in 1998 vs. $3.4 million in 1997) and lower depreciation expenses.
- Expense Increases: Operating expenses rose to $53.8 million, with R&D expenses increasing $9.2 million due to expanded clinical and preclinical programs.
- Liquidity Position: Cash and marketable securities decreased by $14.5 million year-over-year, reflecting net cash used in operating activities of $10.2 million.
Outlook, Risks, and Management Commentary
- Collaboration Milestones: The company received $9.5 million in research progress payments in 1998, including $5.0 million from Sumitomo Pharmaceuticals (BDNF Japan) and $5.0 million from P&G (AXOKINE).
- Clinical Pipeline:
- AXOKINE: Filed an Investigational New Drug (IND) application in Q1 1999; Phase I safety studies for obesity planned for H1 1999.
- BDNF: Intrathecal study for ALS initiated in Q4 1998; subcutaneous study planned for 1999 following retrospective analysis of prior failed Phase III trial.
- NT-3: Clinical studies for constipating conditions ongoing.
- Capital Requirements: The company expects to contribute at least $2.0 million to the Amgen-Regeneron Partners in 1999. Management believes existing capital resources ($113.5 million) are sufficient for at least several years.
- Key Risks:
- Commercialization Uncertainty: No commercial product sales to date; no assurance of future profitability or regulatory approval.
- Collaboration Dependency: Revenue relies heavily on P&G, Amgen, Sumitomo, and Merck. Termination of these agreements would be materially adverse.
- Year 2000 Compliance: Analysis of embedded systems and vendor readiness is incomplete; potential for operational disruption exists.
- Patent Litigation: Ongoing interference proceedings regarding CNTF/AXOKINE patents with Amgen (resolved via covenant not to sue in 1998, but competitive implications remain).
Investor Verification Checklist
- Revenue Concentration: Verify the sustainability of revenue streams from P&G, Amgen, and Merck, as these constitute the entirety of operating revenue.
- Amgen-Regeneron Partners Losses: Monitor the partnership's burn rate and the company's required capital contributions, which impact net loss.
- AXOKINE Clinical Data: Await results of the Phase I safety study scheduled for 1999 to assess the viability of the obesity program.
- Merck Manufacturing Timeline: Confirm the start of production for the Merck vaccine intermediate, as delays could impact future manufacturing revenue.
- Year 2000 Remediation: Review updates on the completion of embedded system analysis and vendor compliance surveys.